Anti-Wnt5a antibody
Specifications
| Product type: | Primary antibody |
| Antigen: | Wnt5a |
| Immunogen: | Recombinant protein |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400-1:2000); Immunohistochemistry(1:40-1:200); Immunocytochemistry (1:40); Flow Cytometry (1:40-1:100) |
| Reactivity: | Human |
| Clonality (clone number): | Monoclonal (G11-5E) |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 1% BSA, 40% glycerol, 0.05% NaN3. |
| Concentration: | 1mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | HWNT 5A antibody |
| HWNT5A antibody | |
| Protein Wnt 5a antibody | |
| Protein Wnt-5a antibody | |
| Protein Wnt5a antibody | |
| Wingless type MMTV integration site family member 5A antibody | |
| Wnt 5a antibody | |
| WNT 5A protein antibody | |
| WNT 5A protein precursor antibody | |
| WNT5A antibody | |
| WNT5A protein precursor antibody | |
| WNT5A_HUMAN antibody |
Target information
igand for members of the frizzled family of seven transmembrane receptors. Can activate or inhibit canonical Wnt signaling, depending on receptor context. In the presence of FZD4, activates beta-catenin signaling. In the presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin degradation through a GSK3-independent pathway which involves down-regulation of beta-catenin-induced reporter gene expression (By similarity). Suppression of the canonical pathway allows chondrogenesis to occur and inhibits tumor formation. Stimulates cell migration. Decreases proliferation, migration, invasiveness and clonogenicity of carcinoma cells and may act as a tumor suppressor. Mediates motility of melanoma cells. Required during embryogenesis for extension of the primary anterior-posterior axis and for outgrowth of limbs and the genital tubercle. Inhibits type II collagen expression in chondrocytes (By similarity).
Provider
Erpantech Laboratory